FDA approves LIKMEZ as the brand name for Metronidazole Oral Suspension (LIKMEZ is a Trademark of Saptalis Pharmaceuticals, LLC) Currently LIKMEZ is the only liquid oral suspension of metronidazole approved in the U.S. Patent coverage provides drug marke
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment
SASKATOON, Saskatchewan--(BUSINESS WIRE)--#bioscience--Across Canada and around the world, Global Biotech Week will be celebrated from September 24 to 30, 2023. In Saskatoon and Regina, Saskatchewan, a mix of industry networking and outreach events are pl
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment
LAVAL, Québec--(BUSINESS WIRE)--#Altasciences--Altasciences is pleased to have been chosen by Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) (“Virpax”), a company specializing in developing non-addictive products for pain management, PTSD, central nervou
Leader in unlocking real-world data for healthcare moves to address the global evidence gap in markets plagued by tight data restrictions and a lack of clinical trial diversityPALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a pioneer in evidence-base
OTTAWA, Ontario--(BUSINESS WIRE)--#ait--BioTalent Canada has issued a new report detailing the success of its national Student Work Placement Program (SWPP) and its positive impact on the severe Labour Market Shortages affecting Canada’s Bioscience indu
FAIRR investor network conducts first-of-its-kind analysis into commitments on regenerative agriculture by 79 global food and retail giants, worth over $3 trillion and representing almost a third of the sector Report available upon requestLONDON--(BUSI
- Phase 2 topline efficacy data for CYB003 on track for Q4 2023, followed by U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2 data for pivotal studies - - Breakthrough Therapy designation anticipated in late 2023, subject to F
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors (“the Board”) has appointed Dr. Robert T. Foster to the Board. MKT Capital Ltd. (together
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.